FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1496898730> ?p ?o ?g. }

• W1496898730 endingPage "9" @default.
• W1496898730 startingPage "2944" @default.
• W1496898730 abstract "The antineoplastic efficacy of P-4055, a 5'-elaidic acid (C18:1, unsaturated fatty acid) ester of cytarabine, a nucleoside antimetabolite frequently used in the treatment of hematological malignancies, was examined in several in vivo models for human cancer. In initial dose-finding studies in nude mice, the efficacy of P-4055 was highest when using schedules with repeated daily doses. In a Raji Burkitt's lymphoma leptomeningeal carcinomatosis model in nude rats, the control cytarabine- and saline-treated animals (five in each group) had a mean survival time of 13.2 days, whereas treatment with P-4055 resulted in three of five long-time survivors (>70 days). In a systemic Raji leukemia model in nude mice, 8 of 10 of the P-4055-treated animals survived (>80 days), compared with none of the cytarabine-treated animals (mean survival time, 34.2 days). In s.c. xenograft models, the effects of maximum tolerated doses of P-4055 and cytarabine, given in four weekly cycles of daily bolus i.v. injections for 5 subsequent days, against seven tumors (three melanomas, one lung adenocarcinoma, one breast cancer, and two osteogenic sarcomas) were investigated. P-4055 induced partial or complete tumor regression of the lung carcinoma, as well as of all three malignant melanomas. In two of the melanomas the activity was highly superior to that of cytarabine, and both P-4055 and cytarabine were, in general, more effective than several clinically established drugs previously tested in the same tumor models. In in vitro studies, inhibitors of nucleoside carrier-dependent transport, nitrobenzylmercaptopurine riboside and dipyridamol, reduced strongly the cellular sensitivity to cytarabine, but not to P-4055, indicating that P-4055 uses an alternative/additional mechanism of internalization into the cell compared with cytarabine. The results explain, at least in part, the observed differences between the two compounds in in vivo efficacy, and together the data strongly support the evaluation of P-4055 in clinical studies." @default.
• W1496898730 created "2016-06-24" @default.
• W1496898730 creator A5018573283 @default.
• W1496898730 creator A5024734577 @default.
• W1496898730 creator A5030845183 @default.
• W1496898730 creator A5034576327 @default.
• W1496898730 creator A5060723543 @default.
• W1496898730 creator A5082518497 @default.
• W1496898730 creator A5085859262 @default.
• W1496898730 date "1999-06-15" @default.
• W1496898730 modified "2023-09-26" @default.
• W1496898730 title "Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models." @default.
• W1496898730 cites W1487811436 @default.
• W1496898730 cites W1539101560 @default.
• W1496898730 cites W1547275364 @default.
• W1496898730 cites W1548495399 @default.
• W1496898730 cites W1828655749 @default.
• W1496898730 cites W1895832174 @default.
• W1496898730 cites W1953582277 @default.
• W1496898730 cites W1957060958 @default.
• W1496898730 cites W1964573195 @default.
• W1496898730 cites W1966542709 @default.
• W1496898730 cites W1969387960 @default.
• W1496898730 cites W1977823334 @default.
• W1496898730 cites W1979518464 @default.
• W1496898730 cites W1991687965 @default.
• W1496898730 cites W2014214643 @default.
• W1496898730 cites W2060897854 @default.
• W1496898730 cites W2085612023 @default.
• W1496898730 cites W2087884039 @default.
• W1496898730 cites W2103880407 @default.
• W1496898730 cites W2107335130 @default.
• W1496898730 cites W2110886624 @default.
• W1496898730 cites W2110964568 @default.
• W1496898730 cites W2119743709 @default.
• W1496898730 cites W2120150472 @default.
• W1496898730 cites W2157768631 @default.
• W1496898730 cites W2169052398 @default.
• W1496898730 cites W2305287298 @default.
• W1496898730 cites W2413953465 @default.
• W1496898730 cites W7050148 @default.
• W1496898730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10383159" @default.
• W1496898730 hasPublicationYear "1999" @default.
• W1496898730 type Work @default.
• W1496898730 sameAs 1496898730 @default.
• W1496898730 citedByCount "15" @default.
• W1496898730 countsByYear W14968987302012 @default.
• W1496898730 countsByYear W14968987302013 @default.
• W1496898730 countsByYear W14968987302014 @default.
• W1496898730 countsByYear W14968987302015 @default.
• W1496898730 countsByYear W14968987302016 @default.
• W1496898730 crossrefType "journal-article" @default.
• W1496898730 hasAuthorship W1496898730A5018573283 @default.
• W1496898730 hasAuthorship W1496898730A5024734577 @default.
• W1496898730 hasAuthorship W1496898730A5030845183 @default.
• W1496898730 hasAuthorship W1496898730A5034576327 @default.
• W1496898730 hasAuthorship W1496898730A5060723543 @default.
• W1496898730 hasAuthorship W1496898730A5082518497 @default.
• W1496898730 hasAuthorship W1496898730A5085859262 @default.
• W1496898730 hasConcept C126322002 @default.
• W1496898730 hasConcept C143998085 @default.
• W1496898730 hasConcept C150903083 @default.
• W1496898730 hasConcept C185592680 @default.
• W1496898730 hasConcept C207001950 @default.
• W1496898730 hasConcept C2776543447 @default.
• W1496898730 hasConcept C2776694085 @default.
• W1496898730 hasConcept C2777333352 @default.
• W1496898730 hasConcept C2777844706 @default.
• W1496898730 hasConcept C2778041864 @default.
• W1496898730 hasConcept C2778397455 @default.
• W1496898730 hasConcept C2780258809 @default.
• W1496898730 hasConcept C71240020 @default.
• W1496898730 hasConcept C71924100 @default.
• W1496898730 hasConcept C86803240 @default.
• W1496898730 hasConcept C98274493 @default.
• W1496898730 hasConceptScore W1496898730C126322002 @default.
• W1496898730 hasConceptScore W1496898730C143998085 @default.
• W1496898730 hasConceptScore W1496898730C150903083 @default.
• W1496898730 hasConceptScore W1496898730C185592680 @default.
• W1496898730 hasConceptScore W1496898730C207001950 @default.
• W1496898730 hasConceptScore W1496898730C2776543447 @default.
• W1496898730 hasConceptScore W1496898730C2776694085 @default.
• W1496898730 hasConceptScore W1496898730C2777333352 @default.
• W1496898730 hasConceptScore W1496898730C2777844706 @default.
• W1496898730 hasConceptScore W1496898730C2778041864 @default.
• W1496898730 hasConceptScore W1496898730C2778397455 @default.
• W1496898730 hasConceptScore W1496898730C2780258809 @default.
• W1496898730 hasConceptScore W1496898730C71240020 @default.
• W1496898730 hasConceptScore W1496898730C71924100 @default.
• W1496898730 hasConceptScore W1496898730C86803240 @default.
• W1496898730 hasConceptScore W1496898730C98274493 @default.
• W1496898730 hasIssue "12" @default.
• W1496898730 hasLocation W14968987301 @default.
• W1496898730 hasOpenAccess W1496898730 @default.
• W1496898730 hasPrimaryLocation W14968987301 @default.
• W1496898730 hasRelatedWork W2096249361 @default.
• W1496898730 hasRelatedWork W2097936686 @default.
• W1496898730 hasRelatedWork W2098840563 @default.

• next